Interactive Features

Quiz

Efficacy of Pirtobrutinib for Heavily-Pretreated MCL

10/30/2023

Findings from the BRUIN trial indicated that BTK inhibitor pirtobrutinib demonstrated durable and encouraging efficacy and safety outcomes among patients with heavily pretreated MCL after covalent BTK inhibitor treatment, with patients...

Findings from the BRUIN trial...

10/30/2023

Oncology

Quiz

Utilizing CAR-HEMATOTOX Score to Predict Treatment Outcomes for R/R MCL

10/20/2023

True or False: In a study assessing the prognostic value of CAR-HEMATOTOX (HT) scores in predicting outcomes among patients with R/R MCL, low baseline scores of 0 to 1 at the time of lymphodepletion before CD19-directed CAR T-cell therapy...

True or False: In a study...

10/20/2023

Oncology

Quiz

Venetoclax, Lenalidomide, and Rituximab Triplet Combination for MCL

10/18/2023

True or False: Findings from a single-arm study on the addition of venetoclax to lenalidomide and rituximab treatment for patients with previously untreated mantle cell lymphoma indicated that patients treated with this triplet combination...

True or False: Findings from a...

10/18/2023

Oncology

Quiz

R-CHOP Plus R-BAC Induction Therapy for Mantle Cell Lymphoma

10/13/2023

True or False: According to a retrospective analysis, the combination of R-CHOP and R-BAC as induction therapy was ineffective in treating transplant-eligible patients with mantle cell lymphoma.

True or False: According to a...

10/13/2023

Oncology

Quiz

Novel Therapeutic Target FGFR1 for Patients With MCL

10/10/2023

True or False: Findings from a study aiming to identify a regulator that directly contributes to the clinical outcomes of mantle cell lymphoma (MCL) indicated that fibroblast growth factor receptor-1 (FGFR1) overexpression in preclinical...

True or False: Findings from a...

10/10/2023

Oncology

Quiz

Significance of DTI for MCL Treatment Outcomes

09/25/2023

True or False: According to findings from a pooled analysis of 3 datasets assessing the potential significance of diagnosis to treatment interval (DTI) for the prognosis of mantle cell lymphoma, patients with shorter DTI were noted to have...

True or False: According to...

09/25/2023

Oncology

Quiz

Pirtobrutinib for High-Risk Subtypes of Mantle Cell Lymphoma

09/19/2023

True or False: Results of the BRUIN trial indicated that after receiving pirtobrutinib, patients with MCL with classical histology had more efficacious outcomes than patients with MCL with blastoid or pleomorphic variants.

True or False: Results of the...

09/19/2023

Oncology

Quiz

Lenalidomide, Rituximab, and Venetoclax Among Patients With Untreated MCL

08/22/2023

True or False: The combination of lenalidomide, rituximab, and venetoclax induced high rates of clinical and molecular responses and demonstrated promising efficacy and safety outcomes among patients with untreated mantle cell lymphoma,...

True or False: The combination...

08/22/2023

Oncology

Quiz

SNPs as Predictive Biomarkers for Lenalidomide Efficacy for MCL

08/14/2023

True or False: In a study assessing the predictive value of single nucleotide polymorphisms (SNPs) among patients with mantle cell lymphoma (MCL), researchers found that specific SNPs represented candidate predictive biomarkers for...

True or False: In a study...

08/14/2023

Oncology

Quiz

Ofatumumab Plus Bendamustine Combination Therapy for MCL

10/18/2022

True or False: Ofatumumab plus bendamustine is an effective and well-tolerated combination therapy for the first-line treatment of older patients with mantle cell lymphoma, according to a phase 2 study.

True or False: Ofatumumab plus...

10/18/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology